Articles
October 24, 2026
Celebrating Caregivers – "The People Who Keep Showing Up for You"
Read Ester's story and insights on caregiving while living with hereditary ATTR amyloidosis, including lessons on resilience, support, and self-care.
Read More ›
October 22, 2026
Alnylam Recognized as a Top Employer by Science Magazine for 8th Year in a Row
Being recognized as a Science Top Employer for eight consecutive years reflects the strength of Alnylam's scientific culture and our continued commitment to innovation, collaboration and excellence.
Read More ›
October 15, 2026
The Signs Were There: How Pete Shaw and His Team Faced an Unexpected Opponent
For former professional football player Pete Shaw, recognizing the signs of hATTR-CM meant looking beyond the expected. Read his story and path to answers.
Read More ›
September 2, 2026
Accelerating the Future of RNAi Drug Discovery with AI
Alnylam and Inceptive are combining RNAi expertise and advanced AI models to accelerate the design of next-generation RNAi therapeutics.
Read More ›
August 26, 2026
Advancing Earlier Diagnosis and Coordinated Care in ATTR-CM
For patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), the path to effective care often begins with a challenge: receiving the right diagnosis before the disease irreversibly advances.
Read More ›
July 20, 2026
Five Keys to Scaling an Innovation Culture
As Alnylam’s clinical pipeline rapidly expands, I’ve found myself reflecting on what has enabled our progress and what it will take to achieve our ambitious 2030 goals.
Read More ›
July 8, 2026
Scaling Responsibly: Alnylam’s Approach to Sustainable Operations
Growth expands our ability to serve patients. It also expands our responsibility for how that work is done. Modern medicines require energy, water, materials, transportation
Read More ›
May 19, 2026
Scaling with Purpose: Alnylam Publishes 2025 Corporate Responsibility Report
Alnylam's 2025 Corporate Responsibility Report details our progress against our corporate responsibility goals in stories and data.
Read More ›
April 7, 2026
2025 Year in Review & Look Ahead: CEO Yvonne Greenstreet on a Transformational Year for Al ...
Alnylam CEO Yvonne Greenstreet reflects on the company's accomplishments in 2025 and highlights of the 2025 annual report.
Read More ›
March 30, 2026
Alnylam Named One of Fast Company's Most Innovative Companies for 2026
RNAi therapeutics pioneer has been recognized by Fast Company as one of the most innovative companies for the 3rd time and ranks #3 in the "Medicines and Therapeutics" category.
Read More ›
FOLLOW US
